RxDoctor Payments Data

Angie Hounsell

Family · Carthage, NCNPI 1649625948

Payments from drug & device makers

$3,431in general payments, 2019–2025

Across 137 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$945
  • AstraZeneca$429
  • Lilly USA, LLC$378
  • AbbVie$350
  • Daiichi Sankyo Inc.$273
  • Boehringer Ingelheim$254
  • plus $801 from 17 others

What the payments were for

  • Food & beverage$3,431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,431 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,268
Medicare patients
137
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$54,235
MounjaroTirzepatide34$36,560
JardianceEmpagliflozin36$34,021
EliquisApixaban22$26,588
TrulicityDulaglutide14$16,213
Levothyroxine Sodium95$1,030
Gabapentin68$1,012
Atorvastatin Calcium119$965
Omeprazole68$884
Rosuvastatin Calcium86$870
Metoprolol Succinate52$808
Amlodipine Besylate150$794
Valsartan15$703
Lidocaine13$701
Fluticasone Propionate52$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$945$54,23558 claims
Lilly USA, LLCMounjaro, Trulicity$378$52,77448 claims
Boehringer IngelheimJardiance$254$34,02136 claims
PfizerEliquis$40$26,58822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Carthage

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →